依达拉奉治疗急性脑梗死的临床观察  

Efficacy and safety of edaravone for acute cerebral infarction

作　　者：王根发[1] 浦政[1] 陈伟[1] 周永炜[1] 李倩[1] 

机构地区：[1]上海第二医科大学附属新华医院,上海200092

出　　处：《中国新药杂志》2005年第11期1342-1344,共3页Chinese Journal of New Drugs

摘　　要：目的:评价依达拉奉治疗急性脑梗死的疗效和安全性。方法:对60例急性脑梗死患者随机分成2组:试验组30例,在一般活血化瘀治疗(丹参+阿司匹林)基础上加用依达拉奉30 mg加入生理氯化钠溶液100 mL,静滴,bid;对照组30例,仅用丹参和阿司匹林,两组疗程均14 d。结果:试验组14 d和30 d评定神经功能缺损欧洲脑卒中评分(ESS)的有效率分别为33.3%和36.7%,对照组为13.3%和16.7%,治疗后d30两组比较差异有显著性(P=0.012);14 d和30 d日常生活能力的有效率,试验组为83.3%和90.0%,对照组为43.3%和53.5%,两组之间差异有显著性(P=0.010和P=0.012)。两组均未见明显的不良反应。结论:依达拉奉治疗急性脑梗死安全有效。Objective：To evaluate the efficacy and safety of edaravone in adults with acute cerebral infarction （ACI）. Methods： Sixty patients with ACI were randomized 1：1 to 2 treatment groups; each group was i.v. infused twice daily over one 14-day treatment period： ①tri-therapy of edaravone 30 mg with Salvia miltiorrhiza injection and aspirin; ② bi-therapy of Salvia mihiorrhiza injection and aspirin. The efficacy at the end of the 14-day therapy and in 30 days post the therapy was assessed using neurological functional deficit scores in terms of ESS and ability of daily life （ADL）. Results：The tri-treated patients experienced significant improvement of ESS evaluation compared with the bi-treated patients 33.3% vs. 13.3% in 14 days and 36.7% vs. 16.7% in 30 days; the P values were 0.010 and 0.012, respectively. Statistical differences of the ADL between the tri-therapy versus bi-therapy were observed（83.3% vs. 43.3% in 14 days, P = 0.01 and 90.0% vs. 53.5% in 30 days, P = 0.012） . No significant incidences of adverse events were reported in both therapies. Conclusion： Edaravone showed an add-on efficacy in the treatment of acute cerebral infarction.

关 键 词：脑梗死 依达拉奉 自由基清除剂 

分 类 号：R969.4[医药卫生—药理学] R971[医药卫生—药学]